FDA Awards PTC Therapeutics Orphan Products Development Grant for the Development of PTC124 in Duchenne Muscular (PR Newswire via Yahoo! Finance)
PTC Therapeutics, Inc. , a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control mechanisms, today announced it has been awarded a two-year grant from the Office of Orphan Products Development Grant Program of the U.S.